FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896972634> ?p ?o ?g. }

• W2896972634 endingPage "327" @default.
• W2896972634 startingPage "321" @default.
• W2896972634 abstract "As a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor (VEGFR2-TKI), apatinib has a certain anti-tumor effect for a variety of solid tumors. The present study evaluates its efficacy and safety in advanced hepatocellular carcinoma (HCC). In this study, 47 patients with advanced HCC were included. TACE monotherapy group included 22 patients that responded to TACE, while the group that received TACE and apatinib included 25 patients that progressed on TACE and were able to receive apatinib off label. Median overall survival (OS) was significantly improved in the apatinib plus TACE group compared with the TACE group. Similarly, apatinib in combination with TACE significantly prolonged median progression-free survival (PFS) compared with TACE monotherapy. Furthermore, there was a significant difference between combination therapy and monotherapy in both Barcelona clinic liver cancer (BCLC) B and BCLC C group. The combination therapy had a dramatic effect on OS and PFS for patients at both BCLC B and BCLC C level. The most common clinically adverse events of apatinib plus TACE group were fatigue, weight loss, hypertension, hand-foot syndrome and anorexia, which were manageable and tolerable. The efficacy analysis showed that there was no significant association of survival benefit with age, gender, Eastern Cooperative Oncology Group (ECOG) performance status, hypertension and hand-foot syndrome. Patients with macrovascular invasion and extrahepatic invasion showed worse survival benefits. In conclusion, apatinib combined with TACE revealed certain survival benefits for HCC patients who experienced progression following TACE, which can provide a promising strategy for HCC treatment." @default.
• W2896972634 created "2018-10-26" @default.
• W2896972634 creator A5002491556 @default.
• W2896972634 creator A5003681868 @default.
• W2896972634 creator A5009707471 @default.
• W2896972634 creator A5012556817 @default.
• W2896972634 creator A5029392163 @default.
• W2896972634 creator A5042177993 @default.
• W2896972634 creator A5053402281 @default.
• W2896972634 creator A5072605704 @default.
• W2896972634 creator A5076636647 @default.
• W2896972634 creator A5080923492 @default.
• W2896972634 date "2018-10-17" @default.
• W2896972634 modified "2023-10-17" @default.
• W2896972634 title "The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study" @default.
• W2896972634 cites W1816099873 @default.
• W2896972634 cites W1859381337 @default.
• W2896972634 cites W1969947714 @default.
• W2896972634 cites W1971837077 @default.
• W2896972634 cites W1994193851 @default.
• W2896972634 cites W1996703005 @default.
• W2896972634 cites W1997533142 @default.
• W2896972634 cites W2022665891 @default.
• W2896972634 cites W2032242790 @default.
• W2896972634 cites W2058887247 @default.
• W2896972634 cites W2079586464 @default.
• W2896972634 cites W2091774189 @default.
• W2896972634 cites W2108118667 @default.
• W2896972634 cites W2113935263 @default.
• W2896972634 cites W2114029473 @default.
• W2896972634 cites W2175687861 @default.
• W2896972634 cites W2180834360 @default.
• W2896972634 cites W2276228008 @default.
• W2896972634 cites W2289095651 @default.
• W2896972634 cites W2568897093 @default.
• W2896972634 cites W2589347272 @default.
• W2896972634 cites W2603421028 @default.
• W2896972634 cites W2611851185 @default.
• W2896972634 cites W2618360530 @default.
• W2896972634 cites W2618523937 @default.
• W2896972634 cites W2730087097 @default.
• W2896972634 cites W2742577150 @default.
• W2896972634 cites W2751140959 @default.
• W2896972634 cites W2752782732 @default.
• W2896972634 cites W2794362009 @default.
• W2896972634 cites W2980018005 @default.
• W2896972634 doi "https://doi.org/10.1080/15384047.2018.1529099" @default.
• W2896972634 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6370378" @default.
• W2896972634 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30332553" @default.
• W2896972634 hasPublicationYear "2018" @default.
• W2896972634 type Work @default.
• W2896972634 sameAs 2896972634 @default.
• W2896972634 citedByCount "32" @default.
• W2896972634 countsByYear W28969726342019 @default.
• W2896972634 countsByYear W28969726342020 @default.
• W2896972634 countsByYear W28969726342021 @default.
• W2896972634 countsByYear W28969726342022 @default.
• W2896972634 countsByYear W28969726342023 @default.
• W2896972634 crossrefType "journal-article" @default.
• W2896972634 hasAuthorship W2896972634A5002491556 @default.
• W2896972634 hasAuthorship W2896972634A5003681868 @default.
• W2896972634 hasAuthorship W2896972634A5009707471 @default.
• W2896972634 hasAuthorship W2896972634A5012556817 @default.
• W2896972634 hasAuthorship W2896972634A5029392163 @default.
• W2896972634 hasAuthorship W2896972634A5042177993 @default.
• W2896972634 hasAuthorship W2896972634A5053402281 @default.
• W2896972634 hasAuthorship W2896972634A5072605704 @default.
• W2896972634 hasAuthorship W2896972634A5076636647 @default.
• W2896972634 hasAuthorship W2896972634A5080923492 @default.
• W2896972634 hasBestOaLocation W28969726341 @default.
• W2896972634 hasConcept C121608353 @default.
• W2896972634 hasConcept C126322002 @default.
• W2896972634 hasConcept C143998085 @default.
• W2896972634 hasConcept C197934379 @default.
• W2896972634 hasConcept C2776231280 @default.
• W2896972634 hasConcept C2776694085 @default.
• W2896972634 hasConcept C2776999253 @default.
• W2896972634 hasConcept C2778019345 @default.
• W2896972634 hasConcept C2778820342 @default.
• W2896972634 hasConcept C2779984678 @default.
• W2896972634 hasConcept C2780668389 @default.
• W2896972634 hasConcept C2780739268 @default.
• W2896972634 hasConcept C31760486 @default.
• W2896972634 hasConcept C71924100 @default.
• W2896972634 hasConcept C90924648 @default.
• W2896972634 hasConceptScore W2896972634C121608353 @default.
• W2896972634 hasConceptScore W2896972634C126322002 @default.
• W2896972634 hasConceptScore W2896972634C143998085 @default.
• W2896972634 hasConceptScore W2896972634C197934379 @default.
• W2896972634 hasConceptScore W2896972634C2776231280 @default.
• W2896972634 hasConceptScore W2896972634C2776694085 @default.
• W2896972634 hasConceptScore W2896972634C2776999253 @default.
• W2896972634 hasConceptScore W2896972634C2778019345 @default.
• W2896972634 hasConceptScore W2896972634C2778820342 @default.
• W2896972634 hasConceptScore W2896972634C2779984678 @default.
• W2896972634 hasConceptScore W2896972634C2780668389 @default.
• W2896972634 hasConceptScore W2896972634C2780739268 @default.
• W2896972634 hasConceptScore W2896972634C31760486 @default.

• next